Starling Oncology annual revenue
2020
2021
2022
2023
2024
2025
Starling Oncology Revenue Growth & History (STLN)
Starling Oncology reported $502.7M in revenue for fiscal 2025, an increase of 27.79% from the previous fiscal year.
View full Starling Oncology company overviewStarling Oncology annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $502.7M | $109.3M | +27.79% |
| 2024 | 2024-12-31 | $393.4M | $69.2M | +21.33% |
| 2023 | 2023-12-31 | $324.2M | $71.8M | +28.42% |
| 2022 | 2022-12-31 | $252.5M | $49.5M | +24.37% |
| 2021 | 2021-12-31 | $203.0M | $15.5M | +8.26% |
| 2020 | 2020-12-31 | $187.5M | — | — |
Starling Oncology quarterly revenue
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $161.3M | $41.5M | +34.62% |
| Q1 2026 | 2026-03-31 | $147.4M | $43.0M | +41.22% |
| Q4 2025 | 2025-12-31 | $142.0M | $41.7M | +41.58% |
| Q3 2025 | 2025-09-30 | $136.6M | $36.7M | +36.70% |
| Q2 2025 | 2025-06-30 | $119.8M | $21.2M | +21.53% |
| Q1 2025 | 2025-03-31 | $104.4M | $9.7M | +10.29% |
| Q4 2024 | 2024-12-31 | $100.3M | $14.5M | +16.88% |
| Q3 2024 | 2024-09-30 | $99.9M | $17.9M | +21.78% |
| Q2 2024 | 2024-06-30 | $98.6M | $18.4M | +22.88% |
| Q1 2024 | 2024-03-31 | $94.7M | $18.5M | +24.25% |
| Q4 2023 | 2023-12-31 | $85.8M | $14.4M | +20.11% |
| Q3 2023 | 2023-09-30 | $82.0M | $17.1M | +26.25% |
| Q2 2023 | 2023-06-30 | $80.2M | $19.3M | +31.69% |
| Q1 2023 | 2023-03-31 | $76.2M | $21.0M | +38.13% |
| Q4 2022 | 2022-12-31 | $71.4M | $19.1M | +36.56% |
| Q3 2022 | 2022-09-30 | $65.0M | $12.7M | +24.30% |
| Q2 2022 | 2022-06-30 | $60.9M | $11.1M | +22.22% |
| Q1 2022 | 2022-03-31 | $55.2M | $6.6M | +13.55% |
| Q4 2021 | 2021-12-31 | $52.3M | — | — |
| Q3 2021 | 2021-09-30 | $52.3M | — | — |
| Q2 2021 | 2021-06-30 | $49.8M | — | — |
| Q1 2021 | 2021-03-31 | $48.6M | — | — |
Starling Oncology revenue growth trends
Over the last five reported fiscal years, revenue grew from $187.5M to $502.7M, a compound annual growth rate of 21.80%. Starling Oncology's latest reported quarter, Q2 2026, generated $161.3M in revenue, an increase of 34.62% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Starling Oncology source filings ↗